NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Jagsonpal Pharma Q4 PAT Jumps 31% to ₹88 Mn; Announces ₹40 Cr Buyback & 200% Dividend
Jagsonpal Pharmaceuticals reported a strong Q4 FY26 with PAT rising 31% YoY to ₹88 Mn, supported by a 10% revenue growth. For the full year FY26, the company achieved a PAT of ₹446 Mn (+19% YoY) and maintained a robust cash balance of ₹191 Cr. The board has approved a ₹40 Cr buyback at ₹250 per share (a significant premium) and a total dividend of 200%, including a special dividend. The company continues to outperform the Indian Pharma Market (IPM) growth rates, particularly through its top 10 brands which constitute 58% of revenue.
முக்கிய அம்சங்கள்
Q4 FY26 PAT grew 31% YoY to ₹88 Mn, while annual FY26 PAT rose 19% to ₹446 Mn.Approved a ₹40 Cr buyback of 16 lakh shares at ₹250/share, representing a ~40% premium to the announcement date price.Recommended a 200% dividend (₹4 per share), including a 75% special dividend, with a total payout of ₹26.2 Cr.Cash and cash equivalents stood at ₹191 Cr as of March 31, 2026, up by ₹45.1 Cr during the year.Outperformed the Indian Pharma Market (IPM) with 12.2% growth compared to 8.6% market growth on a MAT basis.
👀 கவனிக்க வேண்டியவை
Investors should consider the aggressive buyback and special dividend as strong indicators of management's confidence in cash flow and capital efficiency. The company's debt-free status and market outperformance make it a compelling growth-and-income play in the mid-cap pharma space.
Jagsonpal Pharma Recommends Rs 4 Dividend; FY26 Revenue Grows 7% to Rs 2,872 Million
Jagsonpal Pharmaceuticals has recommended a final dividend of Rs. 4 per share (200% of face value) for the financial year ended March 31, 2026. The company's annual revenue from operations increased by 6.9% to Rs. 2,872.25 million compared to the previous year. Despite revenue growth, the annual net profit saw a decline to Rs. 430.82 million from Rs. 553.61 million in FY25. However, Q4 performance was stronger with net profit rising to Rs. 87.62 million from Rs. 65.83 million year-on-year.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs. 4 per equity share (200% of face value Rs. 2)Annual revenue from operations increased to Rs. 2,872.25 million from Rs. 2,687.16 millionFull-year net profit declined to Rs. 430.82 million compared to Rs. 553.61 million in FY25Q4 FY26 net profit grew to Rs. 87.62 million versus Rs. 65.83 million in Q4 FY25Annual Earnings Per Share (EPS) stood at Rs. 6.40, down from Rs. 8.26 in the previous year
👀 கவனிக்க வேண்டியவை
The dividend provides a decent yield, but the decline in annual profitability warrants caution. Investors should watch for margin recovery in upcoming quarters as indicated by the improved Q4 results.
Jagsonpal Pharma Announces Buyback of 16 Lakh Shares at ₹250 Per Share via Tender Offer
Jagsonpal Pharmaceuticals has initiated a postal ballot to seek shareholder approval for a buyback of up to 16,00,000 equity shares at ₹250 per share. The total buyback size is capped at ₹40 crores, representing 18.35% of the company's paid-up capital and free reserves as of March 2025. Crucially, promoters and the promoter group are excluded from this offer, which will be conducted via the tender offer route. The e-voting period for shareholders is scheduled from March 26, 2026, to April 24, 2026.
முக்கிய அம்சங்கள்
Buyback of up to 16,00,000 equity shares (2.39% of total shares) at a price of ₹250 per share.Total buyback size is ₹40 crores, which is 18.35% of the aggregate paid-up capital and free reserves.The offer is via the Tender Offer route, ensuring a proportionate exit for participating shareholders.Promoters and promoter group are specifically excluded from participating in the buyback.15% of the buyback is reserved for small shareholders as per SEBI regulations, potentially increasing their acceptance ratio.
👀 கவனிக்க வேண்டியவை
Investors should compare the current market price with the ₹250 buyback price to assess the premium and potential arbitrage. Small shareholders should consider tendering their shares to benefit from the 15% reservation quota.
Jagsonpal Pharma Announces ₹40 Cr Buyback at ₹250/Share, 40% Premium
Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh shares at a price of ₹250 per share via the tender offer route. This price represents a significant 40% premium over the current market price, with a total outlay of ₹40 crores. Promoters have decided not to participate in the buyback, which will result in their shareholding increasing from 67.2% to 68.9%. The company is utilizing its strong cash position of ₹176 crores to optimize its capital structure and expects a 400 bps improvement in ROCE.
முக்கிய அம்சங்கள்
Buyback of 16 lakh equity shares at ₹250 per share, a 40% premium to market priceTotal buyback size of ₹40 crores represents 18.4% of total paid-up capital and free reservesPromoters will not participate, leading to an increase in promoter stake to 68.9%Company maintains a strong liquidity position with ₹176 crores in free cash as of Dec 2025Expected to improve Return on Capital Employed (ROCE) by approximately 400 basis points
👀 கவனிக்க வேண்டியவை
Investors should look to participate in the tender offer to realize the 40% premium on their holdings. The promoter's decision to stay invested and increase their stake post-buyback signals strong internal confidence in the company's asset-light growth model.
Jagsonpal Pharma Q3 PAT Rises 10% to ₹12.5 Cr; Management Guides for Q4 Recovery
Jagsonpal Pharmaceuticals reported a flattish Q3 FY26 with revenue at ₹73 crores, though PAT grew 10% YoY to ₹12.5 crores. The company faced headwinds as its relevant market (RPM) grew only 3-3.5% compared to the broader pharma market's 8% growth. Management attributed the performance to internal recalibrations and leadership transitions, including a ₹2.1 crore one-time provision for the new labor code. Despite the slow quarter, the company maintains a strong cash position of ₹176 crores and expects double-digit growth to resume from Q4 FY26.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue stood at ₹73 crores, while 9M FY26 revenue grew 6% YoY to ₹223 crores.PAT for the quarter increased by 10% YoY to ₹12.5 crores with margins improving 180 bps to 17.1%.Free cash balance reached ₹176 crores, reflecting an increase of ₹15.2 crores during the quarter.Exceptional item of ₹2.1 crores provided for past service costs related to the new labor code.Management expects growth acceleration to double digits starting from Q4 FY26 following field force recalibration.
👀 கவனிக்க வேண்டியவை
Investors should monitor the promised recovery in Q4 to see if internal leadership changes and strategy refreshes translate into higher volume growth. The strong cash position and debt-free status provide a significant cushion for future expansion or acquisitions.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Jagsonpal Pharma Q3 PAT Rises 10% to ₹125 Mn; 9M PAT Up 12.5% with Strong Cash Reserves
Jagsonpal Pharmaceuticals reported a steady performance for 9MFY26 with Operating PAT growing 12.5% YoY to ₹359 million. While Q3 revenue was largely flat at ₹729 million, the company achieved significant margin expansion, with Operating PAT margins rising 160 bps to 17.1%. A key highlight is the robust cash balance of ₹1,757 million, which increased by ₹152 million during the quarter. Management has expressed confidence in stronger growth starting from Q4 FY26, backed by new product launches and focused initiatives.
முக்கிய அம்சங்கள்
9MFY26 Operating PAT grew 12.5% YoY to ₹359 Mn with margins expanding 95 bps to 16.1%.Q3FY26 Operating PAT increased 10% YoY to ₹125 Mn despite a marginal 1% dip in revenue to ₹729 Mn.Cash and equivalents reached ₹1,757 Mn as of Dec 31, 2025, providing significant liquidity for inorganic growth.Operating EBITDA (pre-ESOP) for 9MFY26 stood at ₹503 Mn, reflecting a 5% YoY increase.The company provided ₹21 Mn in Q3 for potential past service costs related to the new labour code.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to translate its high cash reserves into inorganic growth through brand or business acquisitions. The stock remains attractive due to its asset-light model and margin expansion, but the promised growth acceleration in Q4 will be a key performance indicator.
Jagsonpal Pharma Q3 Net Profit Falls 17.8% YoY to ₹10.98 Cr; Revenue Flat at ₹72.9 Cr
Jagsonpal Pharmaceuticals reported a marginal YoY revenue decline to ₹729.45 million for the quarter ended December 31, 2025. Net profit dropped significantly by 17.8% YoY to ₹109.78 million, primarily weighed down by a ₹20.79 million exceptional charge related to new labor code transitions. While 9-month revenue showed a 6.1% growth to ₹2,230.22 million, overall profitability for the period is lower than the previous year. The company is also dealing with a ₹15.20 million GST demand, which it intends to appeal.
முக்கிய அம்சங்கள்
Q3 Revenue from operations stood at ₹729.45 million vs ₹740.25 million in the previous year's quarter.Net Profit for Q3 declined to ₹109.78 million from ₹133.57 million YoY.Exceptional expense of ₹20.79 million recognized due to the enactment of New Labour Codes affecting employee benefits.9-month revenue grew 6.1% YoY to ₹2,230.22 million, though 9-month profit fell to ₹320.53 million from ₹345.74 million.Company is contesting a ₹15.20 million GST demand from the Haryana SGST office regarding ITC mismatches.
👀 கவனிக்க வேண்டியவை
The decline in both quarterly revenue and profit suggests a challenging operating environment; investors should wait for signs of margin recovery. Monitor the integration of the Yash Pharma business and the resolution of the GST demand for future impact.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
